Jefferies Financial Group Inc. Decreases Stock Holdings in Taysha Gene Therapies, Inc. $TSHA

Jefferies Financial Group Inc. reduced its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 98.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,000 shares of the company’s stock after selling 2,131,642 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Taysha Gene Therapies were worth $138,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in TSHA. Marex Group plc purchased a new stake in shares of Taysha Gene Therapies during the 2nd quarter worth $29,000. E Fund Management Co. Ltd. purchased a new stake in shares of Taysha Gene Therapies during the 2nd quarter worth $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new stake in shares of Taysha Gene Therapies during the 3rd quarter worth $40,000. Tower Research Capital LLC TRC lifted its stake in shares of Taysha Gene Therapies by 156.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after purchasing an additional 10,742 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in shares of Taysha Gene Therapies by 51.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 18,591 shares of the company’s stock worth $43,000 after purchasing an additional 6,350 shares during the last quarter. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Trading Up 1.7%

Shares of NASDAQ:TSHA opened at $5.97 on Tuesday. Taysha Gene Therapies, Inc. has a 52-week low of $2.25 and a 52-week high of $7.30. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of -15.71 and a beta of 1.19. The company has a quick ratio of 14.04, a current ratio of 14.04 and a debt-to-equity ratio of 0.23. The business has a 50-day moving average price of $5.55 and a 200-day moving average price of $5.09.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Equities analysts predict that Taysha Gene Therapies, Inc. will post -0.47 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on TSHA. Needham & Company LLC upped their price objective on Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, March 19th. Wall Street Zen cut Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Chardan Capital reiterated a “buy” rating and issued a $12.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, March 19th. Truist Financial upgraded Taysha Gene Therapies to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, Canaccord Genuity Group increased their price target on Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, April 6th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Taysha Gene Therapies currently has an average rating of “Buy” and an average price target of $11.64.

Insider Activity

In other news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $4.46, for a total value of $892,000.00. Following the completion of the transaction, the insider directly owned 1,136,410 shares in the company, valued at $5,068,388.60. This trade represents a 14.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.78% of the stock is currently owned by insiders.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.